SMMT

Summit Therapeutics Inc
$16.08+$0.28+1.77%Price as of Nov 4, 2026, 5:18 PM ET

Key stats

Market cap
12.8B
Open
—
Day range
—
52-week range
$12.07 – $29.23
Volume
3.86M
Avg volume
5.10M

Earnings

Q3 FY26Upcoming
Expected$-0.29
Q2 FY26
Actual$-0.28
Q1 FY26
Actual$-0.24
Q4 FY25
Actual$-0.29

Next earnings call Nov 14, 2026

About

Summit Therapeutics Inc is a biopharmaceutical company that focuses on the discovery, development, and commercialization of novel antibiotics for serious infectious diseases. Its CDI (Clostridiodes difficile infection) product candidate is ridinilazole, an orally administered small molecule antibiotic. It has two geographical segments: the United States and the United Kingdom.

Employees
265
Headquarters
Miami, FL